Market Overview

Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

Share:
Related GSK
Almost The Whole World In This ETF's Hands
Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares
Amgen's osteoporosis med Prolia shows treatment benefit in patients receiving glucocorticoid therapy (Seeking Alpha)
Related THRX
Theravance Inc Reports Prelim Tender Offer Results
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).

Posted-In: News FDA

 

Related Articles (THRX + GSK)

View Comments and Join the Discussion!